Dávila-Dupont, DavidDavidDávila-DupontMotola-Kuba, DanielDanielMotola-KubaDorantes-Heredia, RitaRitaDorantes-HerediaGonzález-Alonso, Blanca K.Blanca K.González-AlonsoAlcántara-Velarde, ThalíaThalíaAlcántara-VelardeGarcía-Santisteban, RodrigoRodrigoGarcía-SantistebanMartínez-Sámano, Julio EduardoJulio EduardoMartínez-SámanoGrimaldo-Roque, Hiram JosuéHiram JosuéGrimaldo-RoqueRuiz-Morales, José ManuelJosé ManuelRuiz-Morales2022-11-242022-11-242019https://scripta.up.edu.mx/handle/20.500.12552/207810.1159/000497405Purpose: The incidence of pneumonitis reported in previous trials in patients with advanced cancer and use of programmed cell death protein 1 (PD-1) immunotherapy inhibitors was 2.7-3.6%. However, none of these trials included Mexican populations. Methods: This was a retrospective analysis involving 87 patients with advanced cancer who received PD-1 inhibitors as part of their therapy. The primary outcome was the incidence of pneumonitis after using PD-1 inhibitors. The secondary outcomes were major risk factors and radiological patterns of pneumonitis. Results: We found 13 cases of pneumonitis, giving an overall incidence of 15%; three of the cases were high-grade (grade 3). A ground-glass pattern was the major form found by chest computed tomography scans. We did not find any significant risk factor for pneumonitis. Conclusion: The incidence of pneumonitis secondary to treatment with PD-1 inhibitors in our Mexican population was 15%, which is 5 times higher than that found in other studies. No risk factor was identified for this increased incidence of drug-induced pneumonitis following the use of PD-1 inhibitors. © 2019 S. Karger AG, Basel. All rights reserved.Resource Types::text::journal::journal article